Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7.82M
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
1.21M
-
Shares change
-
-2.31M
-
Total reported value, excl. options
-
$3.47M
-
Value change
-
-$6.63M
-
Put/Call ratio
-
7.07
-
Number of buys
-
8
-
Number of sells
-
-18
-
Price
-
$2.86
Significant Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q2 2023
37 filings reported holding PMCB - PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value as of Q2 2023.
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.21M shares
of 7.82M outstanding shares and own 15.51% of the company stock.
Largest 10 shareholders include Ayrton Capital LLC (277K shares), GEODE CAPITAL MANAGEMENT, LLC (219K shares), VANGUARD GROUP INC (184K shares), K2 PRINCIPAL FUND, L.P. (154K shares), CITADEL ADVISORS LLC (64.9K shares), EQUITEC PROPRIETARY MARKETS, LLC (61.4K shares), SIMPLEX TRADING, LLC (47.1K shares), BlackRock Inc. (43.3K shares), DIMENSIONAL FUND ADVISORS LP (29.3K shares), and NORTHERN TRUST CORP (28.4K shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.